Research programme: antibacterials - Roche

Drug Profile

Research programme: antibacterials - Roche

Alternative Names: 3,5-Diamino-piperidinyl triazines (DAPT) compounds - Roche; Bacteria ribosomal translation inhibitors - Roche; Bacterial translation inhibitors - Roche; DAPT antibacterials - Roche

Latest Information Update: 21 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anadys Pharmaceuticals
  • Class Small molecules; Triazines
  • Mechanism of Action Cell wall inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Nosocomial infections

Most Recent Events

  • 04 Apr 2006 This programme is still in active development
  • 25 Jun 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 13 Jun 2002 Preclinical trials in Nosocomial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top